| Name | Title | Contact Details |
|---|
American Competitiveness Institute is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MTM is a medical and transportation management company whose mission is to partner with our clients in developing innovative solutions for accessing healthcare, increasing independence, and connecting community resources in the most cost-effective manner. To achieve our mission and overarching mission of communities without barriers, we leverage our core competencies in managing customer service operations and building provider networks. MTM provides management of transportation, care coordination through home and community based services, call center operations, ambulance claims, and functional assessments and travel training to state and county governments, Medicaid and Medicare managed care organizations (MCOs), third-party administrators, and healthcare providers.
Signature is a Virginia-based multi-family office, offering clients comprehensive strategies and solutions for all aspects of their financial life. With assets under management in excess of $3.7 billion, Signature takes an intelligent approach to creating customized plans for their high net worth individuals and families.
Med 90 Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.